TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38956609
Drug: Mail-order pharmacy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mail-order pharmacy dispensing for medication abortion
Study: 38956676
Drug: Less-invasive surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-invasive surfactant administration (LISA)
Study: 38956809
Drug: Vincristine exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine exposure with a 20% dose increase for low exposure
Study: 38956809
Drug: Vincristine exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine exposure without dose increase
Study: 38957201
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 as an adjuvant therapy to letrozole
Study: 38957349
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 2-week interval between sessions (Experimental Group A)
Study: 38957349
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 4-week interval between sessions (Experimental Group B)
Study: 38958195
Drug: Triptorelin 11.25
Normalized name: triptorelin 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 and 6 months
Study: 38958479
Drug: Eltrombopag monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag monotherapy
Study: 38958845
Drug: New line
Approvals — FDA: no, EMA: no, PMDA: no
Description: New line of therapy following osimertinib and PBC
Study: 38958845
Drug: New line
Approvals — FDA: no, EMA: no, PMDA: no
Description: New line of therapy following osimertinib and PBC (matched subset)
Study: 38958978
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral self-help intervention (12 weekly modules)
Study: 38958989
Drug: Lerodalcibep, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lerodalcibep, 300 mg, subcutaneous injection, monthly for 52 weeks
Study: 38959264
Drug: Increased water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased water supply by 5 L/user/day
Study: 38959480
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin (2.0 mg/kg every 3 weeks)
Study: 38959480
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice: topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
Study: 38959779
Drug: Losmapimod (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod (15 mg twice daily for 52 weeks)
Study: 38960465
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Rapid hepatitis C virus (HCV) antibody testing
Study: 38960465
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Rapid HCV antibody and rapid RNA testing
Study: 38960465
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: Rapid HCV antibody testing and same-day treatment initiation for HCV antibody-positive participants
Study: 38960495
Drug: Social network
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social network intervention (weekly social-health classroom interventions for 9 to 10 months)
Study: 38960626
Drug: ADHD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD treatment responders
Study: 38960832
Drug: ivabradine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (2.5, 5.0, or 7.5 mg) administered twice daily from the morning of surgery until postoperative day 2.
Study: 38960832
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily from the morning of surgery until postoperative day 2.
Study: 38961047
Drug: mAb treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb treatment (casirivimab plus imdevimab 1200 mg)
Study: 38961419
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biomarkers including I-FABP, Alpha-GST, IL-6, PCT, IMA, D-lactate, D-dimer, SCUBE-1, LBP
Study: 38961430
Drug: Health literacy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health literacy and psychoeducational coaching sessions, daily 'Life Hacks', slow-paced breathing exercises, step tracker, low-burden food diary, journaling tool
Study: 38961439
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (ST) only with nivolumab plus ipilimumab
Study: 38961460
Drug: Multimodal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapeutic intervention with additional photobiomodulation therapy (PBMT)
Study: 38962436
Drug: GOE (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOE (900 mg/day)
Study: 38962958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 50) setting step goals and receiving daily feedback
Study: 38963459
Drug: Abiraterone 1000
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone 1000 mg once daily
Study: 38963583
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood (AB) injection: 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl
Study: 38963583
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) injection: 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl
Study: 38963583
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection (AB + CS): 1 ml each of autologous venous blood and 40 mg methylprednisolone acetate along with 1 ml of 2% prilocaine HCl
Study: 38964333
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (LDRT) plus immune checkpoint inhibitors (ICI)
Study: 38964333
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic LDRT plus chemoimmunotherapy
Study: 38964361
Drug: V116 (21-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: V116 (21-valent pneumococcal conjugate vaccine)
Study: 38964420
Drug: Fazirsiran 25
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran 25 mg
Study: 38964420
Drug: Fazirsiran 100
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran 100 mg
Study: 38964420
Drug: Fazirsiran 200
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran 200 mg
Study: 38964799
Drug: Low-dose, non-contrast-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, non-contrast-enhanced thoracic CT scans
Study: 38965031
Drug: Treat-to-target strategy
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target strategy (LDL-C goal of 50-70 mg/dl)
Study: 38965462
Drug: Intracavernous injections
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Study: 38965541
Drug: Single-inhaler triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-inhaler triple therapy (SITT)
Study: 38965541
Drug: Multi-inhaler triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-inhaler triple therapy (MITT)
Study: 38965611
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 40 mg of furosemide intravenously over 10 minutes after fURS
Study: 38965611
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 40 mg of furosemide
Study: 38965611
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment with an alpha-blocker
Study: 38965612
Drug: Concept-guided, personalised,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concept-guided, personalised, motor-cognitive exergame training (twice per week for 30 to 40 minutes)
Study: 38966802
Drug: cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive treatment as usual
Study: 38966851
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Moxidectin (MOX)
Study: 38966851
Drug: 150 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg/kg Ivermectin (IVM)
Study: 38967929
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic formulation consisting of 8 strains from 5 different genera
Study: 38968243
Drug: Multimodal physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal physiotherapy program (supervised exercise with laser-guided feedback and interferential current therapy); 8 treatment sessions (twice per week) over 4 weeks
Study: 38968520
Drug: Anlotinib maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib maintenance therapy
Study: 38969374
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg, max 50 mg) over 40 minutes
Study: 38969374
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL/kg normal saline, max 50 mL) over 40 minutes
Study: 38969378
Drug: Soothing cream
Normalized name: OATMEAL 1 mg in 1 g TOPICAL CREAM [Skin Soothing Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soothing cream gel (SCG)
Study: 38969866
Drug: siRNA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: siRNA and small molecule inhibitors
Study: 38969879
Drug: Metronomic vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic vinorelbine (NVB) monotherapy (n=11)
Study: 38969919
Drug: Somapacitan 5
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Somapacitan 5 mg/1.5 mL
Study: 38969919
Drug: Somapacitan 10
Normalized name: SOMAPACITAN 10 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [SOGROYA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 10 mg/1.5 mL
Study: 38969919
Drug: Somapacitan 5
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Somapacitan 5 mg/1.5 mL and Somapacitan 10 mg/1.5 mL
Study: 38970004
Drug: Digital implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital implant impressions DII with TRIOS 3 Shape intraoral scanner
Study: 38970256
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg twice daily + Temozolomide (TMZ) 60 mg once daily pulsed (7-day schedule)
Study: 38970327
Drug: RSVPreF3 co-administered
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 co-administered with FLU-D-QIV
Study: 38970327
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of RSVPreF3 and FLU-D-QIV
Study: 38970425
Drug: Timrepigene emparvovec
Normalized name: Timrepigene emparvovec
DrugBank: Timrepigene emparvovec (DB16018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timrepigene emparvovec (gene therapy), up to 0.1 mL containing 1 × 10^11 vg/mL, administered bilaterally and sequentially.
Study: 38970713
Drug: No abdominal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No abdominal drain and no prolonged antibiotic prophylaxis
Study: 38970713
Drug: Abdominal drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal drain and prolonged antibiotic prophylaxis
Study: 38971151
Drug: Neoadjuvant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant monotherapy with the PARP inhibitor (PARPi) niraparib
Study: 38971151
Drug: Neoadjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapies
Study: 38971385
Drug: Personalized response-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized response-based adaptive radiation therapy (RT) with concurrent chemoradiation therapy
Study: 38971385
Drug: Personalized response-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized response-based adaptive radiation therapy (RT)
Study: 38971633
Drug: Silicone-based spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-based spray
Study: 38971950
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg on Day 1 every 3 weeks
Study: 38972535
Drug: Post-PCI heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-PCI heparin
Study: 38972535
Drug: Higher hourly
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hourly dose or total doses of heparin
Study: 38972535
Drug: No post-PCI
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-PCI heparin
Study: 38972612
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (400 mg dose)
Study: 38972612
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of 2 × 400 mg of nitrate over 4 weeks
Study: 38972831
Drug: Cytoreductive prostatectomy
Normalized name: GELATIN,ABSORBABLE PROSTATECTOMY CONE,SZ 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive prostatectomy with systemic therapy
Study: 38972831
Drug: Cytoreductive prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive prostate radiotherapy or ablation with systemic therapy
Study: 38972831
Drug: Additional cytoreductive
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional cytoreductive treatment
Study: 38974350
Drug: Parenteral thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral thiamine (100 mg daily for ≥3 d)
Study: 38975302
Drug: l-oxiracetam
Normalized name: oxiracetam
DrugBank: Oxiracetam (DB13601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-oxiracetam
Study: 38975711
Drug: L-tyrosine (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (2000 mg)
Study: 38976126
Drug: SB11 Pre-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB11 Pre-filled Syringe (PFS) administered at a dosage of 0.5 mg via intravitreal injection (IVT).
Study: 38976265
Drug: 24-mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038)
Study: 38976270
Drug: VMP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP 200 mg twice a day
Study: 38976270
Drug: VMP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMP 200 mg twice a day (twin pregnancies)
Study: 38976270
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (twin pregnancies)
Study: 38976363
Drug: Cilofexor 30
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor 30 mg (weeks 1-4), 60 mg (weeks 5-8), 100 mg (weeks 9-12)
Study: 38976448
Drug: Zastaprazan 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zastaprazan 20 mg once daily for 8 weeks
Study: 38976710
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for 12 weeks
Study: 38977298
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (3+1 schedule)
Study: 38977298
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (2+1 schedule)
Study: 38977361
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment with a Pavlik harness for a minimum of 6 weeks
Study: 38977536
Drug: Doxorubicin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin once daily for 6 months
Study: 38977536
Drug: Doxorubicin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy (control group)
Study: 38977651
Drug: ECAP dose-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECAP dose-controlled closed-loop spinal cord stimulation (SCS)
Study: 38977911
Drug: Heparin-coated membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated membrane (HCM)
Study: 38977983
Drug: Preoperative hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hyperglycemia (defined as ≥ 6.1mmol/L)
Study: 38978009
Drug: Multidisciplinary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary medication review using STOPP criteria
Study: 38978009
Drug: Multidisciplinary medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary medication review using START criteria
Study: 38978065
Drug: Universal testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal testing and treatment (UTT) intervention
Study: 38978089
Drug: Decolonization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decolonization with octenisan® wash lotion 1× per day and octenisan® md nasal gel 2-3× per day for 5 days
Study: 38978119
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN) therapy, 3 times a week for 2 weeks
Study: 38978119
Drug: Celecoxib, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 0.2 g/day oral for 2 weeks
Study: 38978119
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN) therapy
Study: 38978117
Drug: Cardio-Metabolic Clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardio-Metabolic Clinic treatment
Study: 38978309
Drug: ACE inhibitors/ARBs
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors/ARBs use
Study: 38978354
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin 10%
Study: 38978405
Drug: CAB+RPV LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB+RPV LA administered every 2 months (Q2M)
Study: 38978512
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (second dose administered at enrollment, day 1)
Study: 38978512
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (first dose administered ≥1 year before enrollment)
Study: 38978512
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (adverse events reported through 15 days after vaccination)
Study: 38978673
Drug: ICV GD2-CART
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICV GD2-CART infusions
Study: 38979062
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil (≥4 consecutive intravenous doses)
Study: 38979073
Drug: Psychophysical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychophysical therapy (received by 73% of AN participants)
Study: 38979756
Drug: TAS-303 18
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-303 18 mg
Study: 38980511
Drug: Adipose tissue
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue injection
Study: 38980678
Drug: Multilevel interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilevel interventions including electronic medical record changes and oral health education and skills training
Study: 38980678
Drug: AAP-based standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAP-based standard oral health education
Study: 38980676
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with orteronel, 300 mg orally twice daily
Study: 38980676
Drug: AD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD therapy with bicalutamide, 50 mg orally daily
Study: 38980675
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Therapy for Insomnia (eCBT-I) delivered over 6 weekly lesson modules with assigned homework activities.
Study: 38980710
Drug: Artificial intelligence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial intelligence-based self-management app (selfBACK) as an adjunct to usual care
Study: 38980968
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol, 100,000 IU, five doses in 3 months)
Study: 38981063
Drug: Previous intravenous
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous intravenous methotrexate treatment